Scopus BioPharma, a preclinical biotech developing immuno-oncology gene therapies for cancer, raised $3 million by offering 0.5 million shares at $5.50, within the range of $5.25 to $5.75. At pricing, the company commands a market value of $80 million. Because the company raised less than $5 million, Scopus BioPharma will be excluded from Renaissance Capital's stats.
Scopus BioPharma plans to list on the Nasdaq under the symbol SCPS. The Benchmark Company acted as a lead manager on the deal.
